Trial Profile
IIT2017-05-MERIN-BLINHMCT: Blinatumomab Plus HLA-Mismatched Cellular Therapy (HMCT) for Relapsed/Refractory CD19+ ALL
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Jul 2023
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary) ; Cell therapies (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 14 Jul 2023 Planned End Date changed from 1 Feb 2024 to 1 Mar 2025.
- 23 Feb 2023 Planned primary completion date changed from 1 Feb 2023 to 1 Jul 2023.
- 23 Feb 2023 Status changed from recruiting to active, no longer recruiting.